Neurosense Therapeutics (NRSN) Granted Key U.S. Patent for Novel PrimeC Formulation, its Lead Asset for ALS and Alzheimer's

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/27/2026

1. SPY
2. AKAM
3. COST
4. META
5. ZS
6. NVDA
7. AWK
8. DRI
9. ULS
10. CRL

Go back to Neurosense Therapeutics (NRSN) Granted Key U.S. Patent for Novel PrimeC Formulation, its Lead Asset for ALS and Alzheimer's
(NASDAQ: NRSN) Delayed: 6.95 -0.45 (6.08%)
Previous Close $7.40    52 Week High $ 
Open $7.18    52 Week Low $ 
Day High $7.18    P/E N/A 
Day Low $6.73    EPS $ 
Volume 8,674